Vanguard Fiduciary Trust
CNTX icon

Vanguard Fiduciary Trust’s Context Therapeutics CNTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
433,888
+92,544
+27% +$188K ﹤0.01% 3520
2026
Q1 		$894K Buy
+341,344
New +$797K ﹤0.01% 2973

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Fiduciary Trust's CNTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Context Therapeutics (CNTX) stake by 27% in Q2 2026, buying an estimated $188K and bringing the position to 433,888 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3520.

Vanguard Fiduciary Trust first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $894K in Q1 2026. 80 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 433,888 shares of Context Therapeutics worth $240K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 92,544 Context Therapeutics shares in Q2 2026, an estimated $188K.
  • Context Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3520 holding.
  • Vanguard Fiduciary Trust first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Context Therapeutics position peaked at $894K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.